The stock of Axovant Sciences Ltd (NYSE:AXON) is a huge mover today! About 254,073 shares traded hands. Axovant Sciences Ltd (NYSE:AXON) has declined 4.22% since April 6, 2016 and is downtrending. It has underperformed by 6.18% the S&P500.
The move comes after 8 months negative chart setup for the $1.19B company. It was reported on Nov, 8 by Barchart.com. We have $10.65 PT which if reached, will make NYSE:AXON worth $59.50M less.
Axovant Sciences Ltd (NYSE:AXON) Ratings Coverage
Out of 4 analysts covering Axovant Sciences (NYSE:AXON), 3 rate it a “Buy”, 1 “Sell”, while 0 “Hold”. This means 75% are positive. Axovant Sciences has been the topic of 4 analyst reports since September 25, 2015 according to StockzIntelligence Inc. As per Friday, September 25, the company rating was maintained by Chardan Capital Markets. The rating was initiated by H.C. Wainwright with “Buy” on Friday, January 8. The company was initiated on Thursday, October 22 by Piper Jaffray. The firm has “Outperform” rating by Leerink Swann given on Tuesday, June 7.
According to Zacks Investment Research, “Axovant Sciences Ltd. is a biopharmaceutical company which focuses on the acquisition, development and commercialization of therapeutics for the treatment of neurodegenerative disorders. Its product candidate includes RVT-101 which is in different clinical trial for the treatment of Alzheimer’s disease and other forms of dementia. Axovant Sciences Ltd. is based in Hamilton, Bermuda.”
More notable recent Axovant Sciences Ltd (NYSE:AXON) news were published by: Prnewswire.com which released: “Axovant Sciences Announces Dementia Pipeline Updates and Reports Financial …” on November 07, 2016, also Fool.com with their article: “Why Axovant Sciences Skyrocketed 56% in November” published on December 03, 2015, Investorplace.com published: “Why Axovant Sciences Ltd (AXON), Jabil Circuit, Inc. (JBL) and Virgin America …” on September 22, 2016. More interesting news about Axovant Sciences Ltd (NYSE:AXON) were released by: Fool.com and their article: “Why Axovant Sciences Shares Are Crashing” published on February 03, 2016 as well as Benzinga.com‘s news article titled: “Axovant Sciences’ Earnings Miss Takes A Backseat To Expected Pipeline Expansion” with publication date: August 16, 2016.
AXON Company Profile
Axovant Sciences Ltd., formerly Roivant Neurosciences Ltd., incorporated on October 31, 2014, is a clinical-stage biopharmaceutical firm focused on acquiring, developing and commercializing therapeutics for the treatment of dementia. The Firm focuses on developing a pipeline of product candidates to address the cognitive, functional and behavioral aspects of dementia and related neurological disorders.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.